ECR 2013 / C-1606
Contrast-enhanced sonography (CEUS) imaging of colorectal cancer (CRC) liver metastasis: comparison with CT in the assessment of response to neoadjuvant, antiangiogenic therapy
Keywords:
Liver, Ultrasound, Contrast agent-other, Metastases
Authors:
O. Catalano1, A. Nunziata2, E. de Lutio di Castelguidone1, G. Nasti1, F. Tatangelo1, A. Petrillo1; 1Naples/IT, 2Ercolano/IT
DOI:
10.1594/ecr2013/C-1606
References
- Anzidei M et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
J Comput Assist Tomogr 2011;35:690-6
- Bertolini F et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
Br J Cancer 2011;104:1079-84
- Chaudhury P et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
HPB (Oxford) 2010;12:37-42
- Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer 2009;45:228-47
- Ismaili N. Treatment of colorectal liver metastases.
World J Surg Oncol 2011;9:154
- Lassau N et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
Radiology 2011;258:291-300
- Nordlinger B et al. European Colorectal Metastases Treatment Group.
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
Eur J Cancer 2007;43:2037-45
- O’Connor JP et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.
Br J Cancer 2011;105:139-45